Physician profile
James G Brooks
NPI 1194788687
$3,890.63
in general payments reported to CMS, 2019-2025
21 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $309 · 2021: $150 · 2022: $450 · 2023: $785 · 2024: $911 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,777.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $943.14 | 2020-2025 | Clareon, Lensx, Unity |
| Glaukos Corporation | $633.81 | 2019-2025 | Photrexa Viscous and Photrexa, Idosetr, Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $628.75 | 2022-2025 | Cequa |
| Allergan, INC. | $420.68 | 2019-2022 | |
| Dompe US, INC. | $329.81 | 2021-2025 | Oxervate |
| Abbvie INC. | $293.79 | 2022-2025 | Lumigan, Vuity, Durysta |
| Bausch & Lomb Americas INC. | $143.29 | 2023-2024 | Miebo, Vyzulta, Xiidra |
| Tarsus Pharmaceuticals, INC. | $103.30 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $58.05 | 2020-2023 | Tecnis Iol |
| Amgen INC. | $49.13 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $48.00 | 2024-2025 | |
| Ocular Therapeutix, INC. | $38.63 | 2019-2023 | Dextenza |
| Thea Pharma INC. | $32.67 | 2023 | Iyuzeh |
| Oyster Point Pharma, INC. | $32.27 | 2023 | Tyrvaya |
| Viiv Healthcare Company | $26.94 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $24.22 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.80 | 2019 | |
| Rxsight INC | $20.72 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Ani Pharmaceuticals, INC. | $16.02 | 2024 | Purified Cortrophin Gel |
| Lemaitre Vascular, INC. | $13.66 | 2024 | Artegraft Vascular Graft |
| Shire North American Group INC | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.